Loading patent…
AssigneeNordic Labs Limited
InventorsVsevolod Ivanovich Kiselev, Irina Gennadievna Vasilyeva
Estimating the term…
The invention relates to pharmacy. It is an object of the present invention to produce nanomicellar structures containing EGCG and achieving a positive result consisting in increasing bioavailability in peroral administration. The object of this invention is achieved by a new pharmaceutical composition for peroral administration containing epigallocatechin-3-gallate as the active component and a target additive that is a block copolymer of oxyethylene and oxypropylene, in which the content of the hydrophobic block is less than 50% by mass and the hydrophilic block has a molecular weight of 2,250 daltons or more at a ratio of the block copolymer to the active component ranging from 1:1 to 10:1. The composition improves absorption of the active compound by the blood flow when delivered perorally.
A pharmaceutical composition for peroral administration containing epigallocatechin-3-gallate as an active component and a target additive, having a block copolymer of oxyethylene and oxypropylene as the target additive wherein the content of a hydrophobic block is less than 50% by mass and a hydrophilic block has a molecular weight of 2,250 daltons or more, at a weight ratio of the block copolymer to the active component ranging from 1:1 to 10:1.
Dependencies are inferred from the claim text.